Menu

Psychiatry

Forest to Acquire U.S. Marketing Rights to Saphris® (asenapine) from Merck

, , , ,

Forest acquires exclusive rights to Saphris® in the United States for the treatment of schizophrenia and acute bipolar mania in adults for $240 million plus sales-based milestones and on-going supply payments Saphris is complementary to Forest’s existing CNS franchise and commercial infrastructure Agreement is expected to be immediately accretive to Forest NEW YORK —  December […]

Forest Laboratories and Gedeon Richter Receive Complete Response Letter for Cariprazine

, , , ,

NEW YORK & BUDAPEST, Hungary–  November 21, 2013 — (BUSINESS WIRE)–Forest Laboratories, Inc. (NYSE:FRX) and Gedeon Richter Plc. announced that the U.S. Food and Drug Administration (FDA) issued a complete response letter regarding the New Drug Application (NDA) for cariprazine, an atypical antipsychotic for the treatment of schizophrenia and for the acute treatment of manic or […]

1 2